Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises
18.11.2025 10:00:00 CET | Business Wire | Press Release
GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces.
Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in black-box autonomous systems – by building trustworthy, transparent, and governed AI agents that accelerate the customer experience (CX) market’s transition from “humans assisted by AI” to “AI powered by humans.”
Unlike other agents on the market, GetVocal’s large language models (LLMs) follow a strict business logic and are only deployed where AI works best – ensuring that humans are in the loop when crucial decisions happen. GetVocal’s CX platform acts as a single governing layer, orchestrating real-time collaboration between human and AI agents in a controlled environment, monitoring every conversation and alerting when human intervention is needed. Designed with the complexities of Europe in mind, the platform reliably supports the gradual shift of responsibilities to AI while maintaining complete transparency, auditability and compliance with the EU AI Act.
“Research by the MIT Media Lab shows that 95 percent of companies fail to get financial value from AI pilots because they lack the skills, processes, and governance to effectively integrate AI. Our customers are proudly in the five percent,” said GetVocal CEO and Co-founder Roy Moussa. “We look forward to restoring confidence in AI agents and offering Europe’s thriving enterprises a pragmatic solution to embed them in their customer experience operations. This funding will directly support the continued development of our hybrid workforce management capabilities and enable us to grow our international team and expand our commercial reach across Europe.”
Major brands such as Vodafone, Glovo, and Movistar already trust GetVocal to simplify and enhance complex customer service interactions, achieving tangible impact at scale, while a pilot is in progress at Deutsche Telekom. For example, Glovo grew its agent fleet from one to 80 AI agents in less than 12 weeks. Bruno Machado, Senior Operations Manager at Glovo, said, “Deploying GetVocal has transformed how we serve our community. From reactivating users to streamlining management, the results speak for themselves: a five-fold increase in uptime and a 35 percent increase in deflection, in just weeks. GetVocal is accelerating our growth and ensuring that we remain a platform users can always count on.”
Compared to existing enterprise solutions, GetVocal’s AI agents drive 31 percent fewer live escalations, 45 percent more self-service resolutions, and achieve a 70 percent deflection rate within three months of launch. This means customers can double efficiency gains while maintaining high satisfaction scores.
GetVocal’s AI agents are fully auditable, adhere to Europe’s strictest data sovereignty requirements and can be deployed on a self-hosted basis, making them ideal for enterprises seeking to prove compliance with the EU AI Act and similar emerging regulations.
“Black-box AI erodes accountability, and legacy contact-centre software locks organisations into rigid workflows unsuitable for day-to-day operations. GetVocal has built a winning platform that enables true automation while providing a level of control over agent behaviour that supports scaling without abandoning responsibility,” explained Hanel Baveja, Partner at Creandum, who will be joining GetVocal’s board.
About GetVocal
GetVocal is the conversational AI platform built for hybrid human-AI workforces. Enterprises rely on GetVocal to build, govern, and optimise hybrid agent fleets - monitoring customer support conversations in real time, intervening instantly, and safely shifting from human to AI service as automation skills evolve. With transparency and control at its core, GetVocal helps organisations modernise customer operations responsibly - without compromising on experience or trust.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251118820169/en/
Contacts
Media contact
Claire Ayles / Reka Agopcsa
Eleven Hundred Agency
T: +44 (0) 20 7688 5202
press@getvocal.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press Release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press Release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press Release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press Release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom